TG Therapeutics TGTX Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's accounts receivable?
- TG Therapeutics (TGTX) reported accounts receivable of $392.05M in Q1 2026.
- How has TG Therapeutics's accounts receivable changed year-over-year?
- TG Therapeutics's accounts receivable increased by 106.2% year-over-year, from $190.12M to $392.05M.
- What is the long-term trend for TG Therapeutics's accounts receivable?
- Over 4 years (2021 to 2025), TG Therapeutics's accounts receivable has grown at a 285.9% compound annual growth rate (CAGR), from $4.48M to $992.65M.
- What does accounts receivable mean?
- The net amount of money customers owe the company for products or services already provided.
- How do you interpret accounts receivable?
- A rising balance relative to revenue may indicate collection issues, while a stable or declining balance suggests efficient cash conversion.
- How does accounts receivable compare across companies?
- Standard across commercial-stage pharmaceutical companies, though dependent on payer mix and contract terms.